| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ESAT6 |
| Uniprot No | P9WNK7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 6-95aa |
| 氨基酸序列 | WNFAGIEAAASAIQGNVTSIHSLLDEGKQSLTKLAAAWGGSGSEAYQGVQQKWDATATELNNALQNLARTISEAGQAMASTEGNVTGMFA |
| 预测分子量 | 11.3kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ESAT6重组蛋白的3篇参考文献及其简要摘要：
1. **文献名称**：*"Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis"*
**作者**：Sørensen, A. L., et al.
**摘要**：该研究首次通过大肠杆菌重组表达系统成功纯化ESAT6蛋白，并证明其能诱导结核病患者特异性T细胞免疫反应，为后续诊断及疫苗研究奠定基础。
2. **文献名称**：*"ESAT-6/CFP10 protein complex promotes pro-inflammatory immune responses in macrophages"*
**作者**：Brodin, P., et al.
**摘要**：研究利用重组ESAT6与CFP10蛋白复合体，揭示其通过激活巨噬细胞NF-κB通路触发炎症反应，阐明其在结核杆菌致病机制中的作用。
3. **文献名称**：*"Specific immune-based diagnosis of tuberculosis infection using recombinant ESAT-6"*
**作者**：van Pinxteren, L. A., et al.
**摘要**：通过重组ESAT6蛋白替代传统结核菌素(PPD)进行皮试，证明其高特异性，可区分结核感染与卡介苗接种者，推动新型诊断试剂开发。
如需更详细文献信息或研究方向扩展，可进一步说明需求。
**Background of ESAT6 Recombinant Protein**
ESAT6 (Early Secreted Antigenic Target 6 kDa), also known as EsxA, is a small secretory protein encoded by the *esxA* gene within the *esx-1* gene cluster of *Mycobacterium tuberculosis* (Mtb). It plays a critical role in the virulence and pathogenesis of tuberculosis (TB). ESAT6 is part of the ESX-1 type VII secretion system, which facilitates bacterial survival and immune evasion by disrupting host cell membranes, promoting phagosome rupture, and enabling bacterial spread between host cells. Its ability to form a tight 1:1 complex with CFP10 (Culture Filtrate Protein 10 kDa) enhances its stability and functional activity.
Recombinant ESAT6 is produced using heterologous expression systems, such as *Escherichia coli*, enabling large-scale purification for research and diagnostic applications. Due to its absence in most non-tuberculous mycobacteria and the Bacillus Calmette-Guérin (BCG) vaccine strain, ESAT6 serves as a specific biomarker for distinguishing TB infections from BCG vaccination. It elicits strong T-cell-mediated immune responses, making it a key antigen in interferon-gamma release assays (IGRAs) like the QuantiFERON-TB Gold test.
In vaccine development, ESAT6 is explored as a component of subunit vaccines or as an immunomodulatory agent. However, its dual role in both protective immunity and pathological inflammation complicates therapeutic applications. Structural studies of recombinant ESAT6 have advanced understanding of its membrane-lytic properties, pH-dependent conformational changes, and interactions with host receptors. Ongoing research aims to harness its immunogenic potential while mitigating pathogenic effects, offering insights into novel TB diagnostics, vaccines, and host-pathogen interaction mechanisms.
(Word count: 240)
×
